受强制性开放获取政策约束的文章 - Thieblemont了解详情
无法在其他位置公开访问的文章：12 篇
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger …
O Hermine, E Hoster, J Walewski, A Bosly, S Stilgenbauer, C Thieblemont, ...
The Lancet 388 (10044), 565-575, 2016
强制性开放获取政策： Lymphoma Research Foundation, USA
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
S Amorim, A Stathis, M Gleeson, S Iyengar, V Magarotto, X Leleu, ...
The Lancet Haematology 3 (4), e196-e204, 2016
强制性开放获取政策： National Institute for Health Research, UK
Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)
E Bachy, V Camus, C Thieblemont, D Sibon, RO Casasnovas, L Ysebaert, ...
Journal of Clinical Oncology 40 (3), 242-251, 2022
强制性开放获取政策： Austrian Science Fund
High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European …
O Hermine, L Jiang, J Walewski, A Bosly, C Thieblemont, M Szymczyk, ...
Journal of clinical oncology 41 (3), 479-484, 2023
强制性开放获取政策： Lymphoma Research Foundation, USA
Ultrahigh-resolution NMR with water signal suppression for a deeper understanding of the action of antimetabolic drugs on diffuse large B-cell lymphoma
G Bertho, L Lordello, X Chen, C Lucas-Torres, IE Oumezziane, ...
Journal of Proteome Research 21 (4), 1041-1051, 2022
强制性开放获取政策： National Institute of Health and Medical Research, France, European …
Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy
C Bommier, E Zucca, S Chevret, A Conconi, G Nowakowski, MJ Maurer, ...
Blood 143 (5), 422-428, 2024
强制性开放获取政策： National Institute of Health and Medical Research, France
Calcium channel blockers impair the antitumor activity of anti-CD20 monoclonal antibodies by blocking EGR-1 induction
I Spasevska, EL Matera, K Chettab, J Ville, M Potier-Cartereau, ...
Molecular Cancer Therapeutics 19 (11), 2371-2381, 2020
强制性开放获取政策： Swiss Cancer League
IBRUTINIB PLUS BR OR R‐CHOP IN PREVIOUSLY TREATED PATIENTS WITH FOLLICULAR OR MARGINAL ZONE LYMPHOMA: THE PHASE 3 SELENE STUDY.
LJ Nastoupil, G Hess, MA Pavlovsky, I Danielewicz, J Freeman, ...
Hematological Oncology 41, 2023
强制性开放获取政策： US National Institutes of Health
Post hoc analyses of patients with relapsed/refractory marginal zone lymphoma who received lenalidomide plus rituximab (R2) vs rituximab/placebo (AUGMENT)
C Thieblemont, J Leonard, M Trneny, K Izutsu, N Fowler, X Hong, ...
Hematological Oncology 37, 226-227, 2019
强制性开放获取政策： US National Institutes of Health
ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated …
Y Karimi, H Ghesquieres, W Jurczak, CY Cheah, MR Clausen, ...
Clinical Lymphoma Myeloma and Leukemia 23, S438, 2023
强制性开放获取政策： US National Institutes of Health
REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort.
C Bommier, M Donzel, C Rossi, L Fornecker, F Bijou, A Chauchet, ...
Hematological Oncology 41, 2023
强制性开放获取政策： National Institute of Health and Medical Research, France
Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B‐cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T‐cell–engaging antibody.
D Soong, C Thieblemont, J Karavitis, B Hess, P Caimi, T Feldman, ...
Hematological Oncology 41, 2023
强制性开放获取政策： German Research Foundation
可在其他位置公开访问的文章：88 篇
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ...
Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022
强制性开放获取政策： US National Institutes of Health
Treatment of older patients with mantle-cell lymphoma
HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ...
New England Journal of Medicine 367 (6), 520-531, 2012
强制性开放获取政策： Lymphoma Research Foundation, USA
Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma
A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, ...
Journal of Clinical Oncology 37 (15), 1285-1295, 2019
强制性开放获取政策： US National Institutes of Health
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ...
Nature medicine 28 (2), 325-332, 2022
强制性开放获取政策： UK Medical Research Council
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
A Younes, P Hilden, B Coiffier, A Hagenbeek, G Salles, W Wilson, ...
Annals of Oncology 28 (7), 1436-1447, 2017
强制性开放获取政策： US National Institutes of Health
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
A Noy, S De Vos, C Thieblemont, P Martin, CR Flowers, F Morschhauser, ...
Blood, The Journal of the American Society of Hematology 129 (16), 2224-2232, 2017
强制性开放获取政策： US National Institutes of Health, National Institute for Health Research, UK
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, ...
Bone marrow transplantation 51 (1), 51-57, 2016
强制性开放获取政策： US National Institutes of Health, Cancer Research UK, National Institute for …
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M Dreyling, F Morschhauser, K Bouabdallah, D Bron, D Cunningham, ...
Annals of Oncology 28 (9), 2169-2178, 2017
强制性开放获取政策： National Institute for Health Research, UK
出版信息和资助信息由计算机程序自动确定